357 results match your criteria bnt162b2


SARS-CoV-2 infection in properly vaccinated healthcare workers.

Int J Infect Dis 2021 Jun 9. Epub 2021 Jun 9.

Hospital Universitario de Canarias, Microbiology Service, Ofra s/n, 38320, La Laguna, Spain. Electronic address:

Background: BNT162b2 mRNA Covid-19 vaccine has shown an optimal protection for population. However the development of SARS-CoV-2 infection has been reported in persons, who have received one or both doses of vaccine. The Hospital Universitario de Canarias began to vaccinate to healthcare workers on Febraury, 2021. Read More

View Article and Full-Text PDF

A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine.

Am J Case Rep 2021 Jun 12;22:e932946. Epub 2021 Jun 12.

Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman.

BACKGROUND The COVID-19 pandemic is an ongoing cause of the current global healthcare crisis. Several vaccines were approved for use by emergency vaccination campaigns worldwide. At present, there are very few reports of COVID-19 vaccine-induced immune-thrombotic thrombocytopenia, a variant of heparin-induced thrombocytopenia (HIT), in comparison to the massive number of vaccinated people worldwide. Read More

View Article and Full-Text PDF

Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients.

J Am Soc Nephrol 2021 Jun 10. Epub 2021 Jun 10.

S Candon, Department of Immunology and Biotherapies, Rouen University Hospital, Rouen, France.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a high rate of mortality in patients with end stage renal disease and vaccination is hoped to prevent infection. Between January 18, and February 24, 2021, 225 kidney transplant recipients (KTR) and 45 hemodialysis patients (HDP) received two injections of mRNA BNT162b2 vaccine. The post-vaccinal humoral and cellular response was explored in the first 45 KTR and 10 HDP. Read More

View Article and Full-Text PDF

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.

Nature 2021 Jun 10. Epub 2021 Jun 10.

Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve around the world, generating new variants that are of concern based on their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutics. Here we report that 20 human sera, drawn 2 or 4 weeks after two doses of BNT162b2, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the newly emerged B.1. Read More

View Article and Full-Text PDF

Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine.

J Stroke Cerebrovasc Dis 2021 May 25;30(8):105906. Epub 2021 May 25.

Department of Neurology, Centro Hospitalar Universitário de São João, E.P.E., Porto, Portugal; Clinical Neurosciences and Mental Health Department, Faculty of Medicine of the University of Porto, Portugal.

The development of SARS-CoV-2 vaccines has raised several concerns regarding venous thromboembolism, namely cerebral venous thrombosis. Although cerebral venous thrombosis has been reported after administration of a viral vector vaccine, due to a possible auto-immune mechanism inducing thrombocytopenia, the same has not happened in mRNA vaccines. We report two cases of cerebral venous thrombosis, shortly after administration of mRNA vaccine. Read More

View Article and Full-Text PDF

Socioeconomic disparities and COVID-19 vaccination acceptance: a nationwide ecologic study.

Clin Microbiol Infect 2021 Jun 7. Epub 2021 Jun 7.

the B. Rappaport Faculty of Medicine, Technion, Haifa, Israel; The department of Cardiology, Rambam Health Care Campus. Electronic address:

Objective: To analyze the correlation between COVID-19 vaccination percentage and socioeconomic status (SES).

Methods: A nationwide ecologic study based on open-sourced, anonymized, aggregated data provided by the Israel Ministry of Health. The correlations between municipal SES, vaccination percentage, and active COVID-19 cases during the vaccination campaign were analyzed by using weighted Pearson correlations. Read More

View Article and Full-Text PDF

SYMPTOMATIC SARS-CoV-2 INFECTIONS AFTER FULL SCHEDULE BNT162b2 VACCINATION IN SEROPOSITIVE HEALTHCARE WORKERS: A CASE SERIES FROM A SINGLE INSTITUTION.

Emerg Microbes Infect 2021 Jun 10:1-6. Epub 2021 Jun 10.

Department of Medicine and Surgery, University of Insubria, Varese, Italy.

We report 11 cases of SARS-CoV-2 infection in healthcare workers (HCW) for COVID-19 and seropositive after the second dose of the BNT162b2 mRNA vaccine. Based on voluntary-based surveillance, they tested positive for different strains of SARS-CoV-2, as Spike gene sequencing showed. Five of them reported mild symptoms. Read More

View Article and Full-Text PDF

A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020-February 2021.

Lancet Reg Health Eur 2021 Aug 5;7:100130. Epub 2021 Jun 5.

Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 6139001, Israel.

Background: Social inequalities affect the COVID-19 burden and vaccine uptake. The aim of this study was to explore inequalities in the incidence and mortality rate of SARS-CoV-2 infection and vaccine uptake in various sociodemographic and population group strata in Israel.

Methods: We analysed nationwide publicly available, aggregated data on PCR-confirmed SARS-CoV-2 infections and COVID-19 deaths between March 2020 and February 2021, as well as the first three months of COVID-19 immunisation according to sociodemographics, including population group and residential socioeconomic status (SES). Read More

View Article and Full-Text PDF

Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine.

EClinicalMedicine 2021 Jun 4:100928. Epub 2021 Jun 4.

Scientific Direction, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy.

Background: Literature data suggests that age, gender and body mass index (BMI) could be associated with difference in immune responses to vaccines. The first goal of the study was to analyze the antibody titre seven days after the second dose of BNT162b2 vaccine in a group of 248 healthcare workers (HCWs). The second goal was to analyze how antibody titre changes in correlation with age, gender, BMI and hypertension. Read More

View Article and Full-Text PDF

Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom.

Nat Med 2021 Jun 9. Epub 2021 Jun 9.

National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, UK.

The effectiveness of COVID-19 vaccination in preventing new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the general community is still unclear. Here, we used the Office for National Statistics COVID-19 Infection Survey-a large community-based survey of individuals living in randomly selected private households across the United Kingdom-to assess the effectiveness of the BNT162b2 (Pfizer-BioNTech) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca; ChAdOx1) vaccines against any new SARS-CoV-2 PCR-positive tests, split according to self-reported symptoms, cycle threshold value (<30 versus ≥30; as a surrogate for viral load) and gene positivity pattern (compatible with B.1. Read More

View Article and Full-Text PDF

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.

Nat Med 2021 Jun 9. Epub 2021 Jun 9.

Usher Institute, University of Edinburgh, Edinburgh, UK.

Reports of ChAdOx1 vaccine-associated thrombocytopenia and vascular adverse events have led to some countries restricting its use. Using a national prospective cohort, we estimated associations between exposure to first-dose ChAdOx1 or BNT162b2 vaccination and hematological and vascular adverse events using a nested incident-matched case-control study and a confirmatory self-controlled case series (SCCS) analysis. An association was found between ChAdOx1 vaccination and idiopathic thrombocytopenic purpura (ITP) (0-27 d after vaccination; adjusted rate ratio (aRR) = 5. Read More

View Article and Full-Text PDF

Economic evaluation for mass vaccination against COVID-19.

J Formos Med Assoc 2021 May 25. Epub 2021 May 25.

School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan. Electronic address:

Background: Vaccine is supposed to be the most effective means to prevent COVID-19 as it may not only save lives but also reduce productivity loss due to resuming pre-pandemic activities. Providing the results of economic evaluation for mass vaccination is of paramount importance for all stakeholders worldwide.

Methods: We developed a Markov decision tree for the economic evaluation of mass vaccination against COVID-19. Read More

View Article and Full-Text PDF

Acquired Thrombotic Thrombocytopenic Purpura: a rare disease associated Acquired with BNT162b2 vaccine.

J Thromb Haemost 2021 Jun 8. Epub 2021 Jun 8.

Department of Hematology, Shamir Medical Center, Zerifin, Israel.

In December 2020 the Israeli Health Ministry began a mass vaccination campaign with the BNT162b2 vaccine. This was an important step in overcoming the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic. Autoimmune phenomenon have been described after receiving vaccinations. Read More

View Article and Full-Text PDF

Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany.

Emerg Infect Dis 2021 Jun 8;27(8). Epub 2021 Jun 8.

We detected delayed and reduced antibody and T-cell responses after BNT162b2 vaccination in 71 elderly persons (median age 81 years) compared with 123 healthcare workers (median age 34 years) in Germany. These data emphasize that nonpharmaceutical interventions for coronavirus disease remain crucial and that additional immunizations for the elderly might become necessary. Read More

View Article and Full-Text PDF

Effectiveness of SARS-CoV-2 vaccination in fully-vaccinated solid organ transplant recipients.

Am J Transplant 2021 Jun 8. Epub 2021 Jun 8.

Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA.

The COVID-19 pandemic has disproportionately impacted immunosuppressed patients, including solid organ transplant recipients (SOTR). COVID-19-associated mortality among SOTR was estimated at 20.5% in the early phase of the pandemic(1). Read More

View Article and Full-Text PDF

Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients.

J Clin Invest 2021 Jun 8. Epub 2021 Jun 8.

Department for General and Visceral Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Novel mRNA-based vaccines have been proven powerful tools to combat the global pandemic caused by SARS-CoV2 with BNT162b2 (trade name: Comirnaty) efficiently protecting individuals from COVID-19 across a broad age range. Still, it remains largely unknown how renal insufficiency and immunosuppressive medication affect development of vaccine induced immunity. We therefore comprehensively analyzed humoral and cellular responses in kidney transplant recipients after the standard second vaccination dose. Read More

View Article and Full-Text PDF

The Israeli study of Pfizer BNT162b2 vaccine in pregnancy: considering maternal and neonatal benefits.

J Clin Invest 2021 Jun 8. Epub 2021 Jun 8.

Division of Reproductive Sciences, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, United States of America.

Pregnant patients with COVID-19 are more likely to require intensive care and die compared with non-infected pregnant women. While the consequences of COVID-19 disease in pregnancy prompted many health care organizations to support vaccination in pregnancy, vaccine effects for mother and infant remained unclear. In this issue of the JCI, Beharier and Mayo et al. Read More

View Article and Full-Text PDF

Use of COVID-19 vaccines in patients with liver disease and post-liver transplantation: Position statement of the Saudi association for the study of liver diseases and transplantation.

Saudi J Gastroenterol 2021 May 29. Epub 2021 May 29.

College of Medicine, Alfaisal University, Riyadh; Department of Medicine, Gastroenterology Section, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Patients with chronic liver disease (CLD) and liver transplant recipients are at increased risk of morbidity and mortality from coronavirus disease 2019 (COVID-19). Although several studies demonstrated the safety and efficacy of COVID-19 vaccines in the general population, data in CLD patients and liver transplant recipients are lacking. Two COVID-19 vaccines were approved by the Saudi Food and Drug Authority and rolled out to several million recipients in Saudi Arabia. Read More

View Article and Full-Text PDF

Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient.

Mult Scler 2021 Jun 8:13524585211022037. Epub 2021 Jun 8.

Jacobs Comprehensive MS Treatment and Research Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA.

View Article and Full-Text PDF

Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.

AAPS PharmSciTech 2021 Jun 7;22(5):172. Epub 2021 Jun 7.

Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Tampa Bay Campus, Clearwater, FL, USA.

Vaccination development and production was an essential question for the prevention and global control of COVID-19. The strong support from governing authorities such as Operation Warp Speed and robust funding has led to the development and authorization of the tozinameran (BNT162b2) vaccine. The BNT162b2 vaccine is a lipid nanoparticle-encapsulated mRNA that encodes for SARS-CoV-2 spike protein, the main site for neutralizing antibodies. Read More

View Article and Full-Text PDF

Functional characterization of SARS-CoV-2 vaccine elicited antibodies in immunologically nave and pre-immune humans.

bioRxiv 2021 May 31. Epub 2021 May 31.

As the COVID-19 pandemic continues, the authorization of vaccines for emergency use has been crucial in slowing down the rate of infection and transmission of the SARS-CoV-2 virus that causes COVID-19. In order to investigate the longitudinal serological responses to SARS-CoV-2 natural infection and vaccination, a large-scale, multi-year serosurveillance program entitled SPARTA (SARS SeroPrevalence and Respiratory Tract Assessment) was initiated at 4 locations in the U.S. Read More

View Article and Full-Text PDF

Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.

JAMA Netw Open 2021 06 1;4(6):e2115985. Epub 2021 Jun 1.

Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Importance: The BNT162b2 vaccine showed high efficacy against COVID-19 in a phase III randomized clinical trial. A vaccine effectiveness evaluation in a real-world setting is needed.

Objective: To assess the short-term effectiveness of the first dose of the BNT162b2-vaccine against SARS-CoV-2 infection 13 to 24 days after immunization in a real-world setting. Read More

View Article and Full-Text PDF

Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers.

EClinicalMedicine 2021 Jun 31;36:100914. Epub 2021 May 31.

Occupational Health Unit, International Centre for Rural Health, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.

Background: Health care workers (HCWs) are at high risk of contracting an infection by SARS CoV-2 and thus they are a priority for vaccination. We hereby aim to investigate whether the risk of severe and moderate systemic symptoms (MSS) after vaccination is higher in HCWs with a history of previous COVID-19.

Methods: An online questionnaire was offered to the cohort all HCWs undergoing anti-SARS CoV-2 mRNA BNT162b2 vaccination between January 4th and February 9th 2021 in two large tertiary hospitals (ASST Santi Paolo and Carlo) in Milan, Italy. Read More

View Article and Full-Text PDF

Myocarditis following COVID-19 mRNA vaccination.

Vaccine 2021 May 28. Epub 2021 May 28.

Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa, Israel; Department of Nephrology, Hillel Yaffe Medical Center, Hadera, Israel.

Background: Clinical trials of the BNT162b2 vaccine, revealed efficacy and safety. We report six cases of myocarditis, which occurred shortly after BNT162b2 vaccination.

Methods: Patients were identified upon presentation to the emergency department with symptoms of chest pain/discomfort. Read More

View Article and Full-Text PDF

Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.

Emerg Microbes Infect 2021 Jun 7:1-6. Epub 2021 Jun 7.

Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.

View Article and Full-Text PDF

COVID-19 vaccine hesitancy: Lessons from Israel.

Authors:
David Gurwitz

Vaccine 2021 May 27. Epub 2021 May 27.

Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel. Electronic address:

View Article and Full-Text PDF

COVID-19 vaccines in patients with cancer.

Lancet Oncol 2021 06;22(6):738-739

European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; Department of Oncology and Hematology, University of Milan, Milan, Italy. Electronic address:

View Article and Full-Text PDF

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.

Br J Haematol 2021 Jun 3. Epub 2021 Jun 3.

Department of Clinical Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have been classified in the clinically extremely vulnerable group to develop severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), including patients with chronic myeloid leukaemia (CML) taking TKIs. In addition, concerns that immunocompromised individuals with solid and haematological malignancies may not mount an adequate immune response to a single dose of SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine have been raised. In the present study, we evaluated humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 patients with CML. Read More

View Article and Full-Text PDF